TickerFacts.

Scynexis Inc (SCYX): Revenue

Annual figures by period end, from SEC filings.

$20.60M
Year ended 2025-12-31
$19.22M
Trailing 12 months to 2026-06-30
+59.4%
3-year compound annual growth
n/m
10-year compound annual growth
$140.14M2013-12-31: $16.86M2014-12-31: $1.26M2015-12-31: $257.0K2016-12-31: $257.0K2017-12-31: $257.0K2018-12-31: $257.0K2019-12-31: $121.0K2020-12-31: $02021-12-31: $13.16M2022-12-31: $5.09M2023-12-31: $140.14M2024-12-31: $3.75M2025-12-31: $20.60M$20.60M
2013-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$20.60M+449.9%2026-03-04, From 2025-01-01
2024-12-31$3.75M-97.3%2026-03-04, From 2024-01-01
2023-12-31$140.14Mn/m2025-03-12, From 2023-01-01
2022-12-31$5.09M-61.3%2024-03-28, From 2022-01-01
2021-12-31$13.16Mn/a2023-03-31, From 2021-01-01
2020-12-31$0-100.0%2022-03-29, From 2020-01-01
2019-12-31$121.0K-52.9%2021-03-29, From 2019-01-01
2018-12-31$257.0K0.0%2020-03-11, From 2018-01-01
2017-12-31$257.0K0.0%2019-03-14, From 2017-01-01
2016-12-31$257.0K0.0%2018-03-13, From 2016-01-01
2015-12-31$257.0K-79.5%2017-03-13, From 2015-01-01
2014-12-31$1.26M-92.5%2017-03-13, From 2014-01-01
2013-12-31$16.86Mn/a2015-03-30, From 2013-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Scynexis Inc (SCYX)2025-12-31$20.60M+449.9%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$20.71M-27.4%
Evofem Biosciences, Inc. (EVFM)2025-12-31$20.18M+4.2%
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$19.39M+68.0%
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31$22.50M-50.6%
Alumis Inc. (ALMS)2025-12-31$24.05Mn/a
Entrada Therapeutics, Inc. (TRDA)2025-12-31$25.42M-87.9%
uniQure N.V. (QURE)2025-12-31$16.10M-40.6%
Celularity Inc (CELU)2025-12-31$26.55M-51.0%

Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗